Recent Updates
Recently added Catalysts

VRVg-2

Phase 3

Rabies (Healthy Volunteers) | Monoclonal antibody | Other |Sanofi|Last Updated: Sep 18, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment640
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03965962Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in AdultsPHASE3 COMPLETED 640Jul 1, 2019Jul 1, 2021Sep 18, 20252 France
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titers Greater Than or Equal to (>=) 0.5 International Units Per Milliliter (IU/mL)-Non-Inferiority Analysis
Day 28

RVNA titer against rabies virus was assessed using the Rapid Fluorescent Focus Inhibition test (RFFIT) assay method.

Secondary Endpoints
Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >=0.5 IU/mL
Day 0 (pre-vaccination), Day 14, Day 28 and Day 42
Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >=0.2 IU/mL (Lower Limit of Quantification [LLOQ])
Day 0 (pre-vaccination), Day 14, Day 28 and Day 42
Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus
Day 0 (pre-vaccination), Day 14, Day 28 and Day 42
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Group 1: VRVg-2 + HRIGEXPERIMENTALParticipants received 0.5 milliliters (mL) intramuscular (IM) injection of VRVg-2 formulation on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0.
Group 2: Verorab + HRIGACTIVE_COMPARATORParticipants received 0.5 mL IM injection of Verorab on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0.
Group 3: Imovax Rabies + HRIGACTIVE_COMPARATORParticipants received 1 mL IM injection of Imovax Rabies on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0.
Group 4: VRVg-2EXPERIMENTALParticipants received 0.5 mL IM injection of VRVg-2 formulation on Days 0, 3, 7, 14 and 28.
Interventions
NameTypeDescription
VRVg-2BIOLOGICALPharmaceutical form: Powder and solvent for suspension for injection; Route of administration: IM
Purified Inactivated Rabies VaccineBIOLOGICALPharmaceutical form: Powder and solvent for suspension for injection; Route of administration: IM
Human Diploid Cell Vaccine (HDCV)BIOLOGICALPharmaceutical form: Powder and solvent for suspension for injection; Route of administration: IM
Rabies immune globulin (human)BIOLOGICALPharmaceutical form: Solution for injection; Route of administration: IM
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion criteria : * Men or women aged \>=18 years on the day of inclusion (\>= 18 years means from the day of the 18th birthday onwards, with no upper age limit). * Able to attend all scheduled visits and to comply with all trial procedures. * Body Mass Index (BMI): 18.5 kilograms per square met...

Countries:France
Unlock Eligibility Criteria